Large gap with delayed quotes
|
Last quote
11/28/2025
-
23:00:00
|
Bid
11/28/2025 -
18:59:58
|
Bid Volume |
Ask
11/28/2025 -
18:59:58
|
Ask Volume |
|---|---|---|---|---|
|
780.19
-4.42
(
-0.56% )
|
780.18
|
40 |
780.85
|
40 |
Analysis date: 28.11.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 28.10.2025.
Interest
Strong
Strong
Three stars since 28.10.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 28.10.2025 at a price of 654.48.
Evaluation
Overvalued
Overvalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 04.07.2025.
4wk Rel Perf
19.95%
19.95%
The four-week dividend-adjusted overperformance versus SP500 is 19.95%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 28.10.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.39%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.54%.
Mkt Cap in $bn
82
82
With a market capitalization >$8bn, REGENERON PHARMA is considered a large-cap stock.
G/PE Ratio
0.92
0.92
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
13.21
13.21
The estimated PE is for the year 2027.
LT Growth
11.70%
11.70%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
21
21
Over the last seven weeks, an average of 21 analysts provided earnings per share estimates.
Dividend Yield
0.48%
0.48%
The twelve month estimated dividend yield represents 6.29% of earnings forecasts.
Beta
56
56
For 1% of index variation, the stock varies on average by 0.56%.
Correlation
0.26
0.26
Stock movements are strongly independent of index variations.
Value at Risk
412.04
412.04
The value at risk is estimated at USD 412.04. The risk is therefore 52.81%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
02.04.2004
02.04.2004